News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dicerna Pharmaceuticals Announces That Kyowa Hakko Kirin Has Selected a Second DsiRNA Therapeutic Candidate for Development, Triggering $5 Million Milestone Payment


1/3/2013 9:47:23 AM

WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Dicerna), a RNA interference (RNAi) company focused on developing breakthrough oncology therapeutics, today announced that Kyowa Hakko Kirin Co., Ltd. (KHK) (TSE: 4151) has elected to advance the second therapeutic oncology candidate from the research to development stage. The achievement of this milestone triggers a $5 million payment from KHK to Dicerna.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES